Translational Research Grant

The Translational Research Grant, offered by RNID, aims to expedite the development of innovative treatments for hearing loss and tinnitus. With funding up to £300K, it supports projects from academic and small/medium enterprises worldwide. Eligible proposals must present novel therapeutic solutions, robust experimental plans, and clear commercial potential. The 2026 application cycle is set to launch in early 2026, following the closure of the 2025 scheme.

NOTE: The deadline for the 2025 scheme has passed. The 2026 scheme will launch in early 2026.
Translational Grant
The Translational Grant aims to support and accelerate the translation of research discoveries into potential new treatments to protect and regenerate hearing and /or silence tinnitus. It funds projects at both academic institutions and small/medium enterprises in any country.
Research focused on the development of a specific novel therapeutic for the treatment of hearing loss and/or tinnitus.Clearly defined experimental plans supported by relevant preliminary and/or proof-of-concept data.Proposals that clearly outline the commercial potential of the therapeutic and describe how work undertaken during the Translational Research Grant will enable the innovation to attract follow-on funding for subsequent developmental steps.
Value
Up to £300K in total, funding will not exceed £100K in one year